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Recent evidence suggests that the malfunctioning disposal system of cell protein called ubiquitin–proteasome
system (UPS) plays an important role in the development of disorders, including cancer and neurodegenera-
tive diseases. Accumulating evidence suggests that the abnormal regulation of the E3 ubiquitin ligases,
essential components of the UPS, contributes to uncontrolled proliferation, genomic instability and cancer,
since these ligases and their substrates are involved in the regulation of cell cycle progression, gene
transcription, signal transduction, DNA replication and others. Through selective degradation of speciﬁc
substrates, E3 ligases regulate different biological processes. Cullins are a family of proteins that confer
substrate speciﬁcity to multimeric complex of E3 ligases acting as scaffold proteins. So far, seven members of
the cullin family of proteins have been identiﬁed. Interestingly, the data generated by several groups indicate
that cullin 3 (Cul3) has begun to emerge as a protein involved in the etiopathology of multiple diseases. In this
paper we examine the latest advances in basic research on the biology of Cul3 and how it could help to direct
drug discovery efforts on this target.
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Open access under CC BY license. Protein degradation: the proteasomal system
In order to maintain cell functionality and viability, it is important
that damaged, altered, misfolded or unnecessary proteins can be
recognized and degraded. One of the most important systems for
protein degradation is the ubiquitin–proteasome system (UPS) [1,2].
This system is found in both the nucleus and the cytoplasm [3],
where it regulates vital cellular processes. For example, the cell cycle
progression is regulated by the degradation of cyclins and inhibitors
of cyclin-dependent kinases [4]. Moreover, UPS is involved in
the regulation of cell growth and gene expression by degrading
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[6] and β-catenin [7], as well as in the termination of signaling
cascades through protein degradation of activated kinases. Thus, the
interest in the study of the involvement of UPS in the degradation of
proteins has become more relevant since the deregulation of this
system has been implicated in the pathogenesis of human diseases,
such as malignancies and neurodegenerative processes [8,9].
Degradation via the UPS system is mediated by a process called
ubiquitination [2], where ubiquitin is attached to the target
protein by a peptide linkage, allowing its transport to the 26S
proteasome complex. Ubiquitination is a complex process that
involves several steps, and is mediated by a series of enzymes,
including an ubiquitin-activating enzyme (E1, UAE, also known as
UBA1), ubiquitin-conjugating enzyme (E2) and ubiquitin ligase
(E3) [10]. The substrate recognition for ubiquitination is highly
speciﬁc and this activity can be provided by the E3 ubiquitin
ligases.Ubiquitin ligases (E3)
The E3 ubiquitin ligases are the largest group of enzymes
involved in the UPS. In contrast to the E1 and E2 enzymes,
ubiquitin ligases (E3) are highly diverse; so far over 500 ubiquitin
ligases have been identiﬁed, and this has allowed the suggestion
that E2 may be associated with different E3 ligases, resulting in a
large amount of E2/E3 functional complexes, and consequently, in
a high number of speciﬁc target substrates [1,11]. The ubiquitin
ligases are classiﬁed into two main classes: the ﬁrst one is the E3
ligase with HECT domain (homologous to the E6-AP carboxyl
terminus domain), whereas the second one is the E3 ligase with
RING ﬁnger domain (a really interesting new gene) [12,13]. Ligases
of this second class are based on cullin (CRL: cullin-RING ubiquitin
ligases), which are the common type of ubiquitin ligases known
so far [14].Table 1
Components and adapters of CRLs complexes.
Cullin E3 complex components Adapter
1 Skp1-Cul1-F-box-ROC1/Rbx1 Skp1
2 Elongin BC-Cul2-Protein SOCS-ROC1/Rbx1 ElonginC/ElonginB
3 BTB-Cul3-ROC1/Rbx1 Protein Protein BTB, BTB domain
4A, 4B DDB1-Cul4A/4B-DDB2 o CSA-ROC1/Rbx1 DDB1
5 Elongin BC-Cul5-Protein SOCS-ROC1/Rbx1 ElonginC/ElonginB
7 Skp1-Cul7-Fbx29-ROC1/Rbx1 Skp1
Skp1: S-phase kinase-associated protein 1; F-box: motif that functions as a site of
protein–protein interaction; ROC1/Rbx1: RING-box protein; BTB: bric-a-brac/tram-
track/broad-complex; DDB1: damage-speciﬁc DNA binding protein 1; SOCS: suppres-
sors of cytokine signaling protein; CSA: cockayne syndrome group A protein.
Fig. 1. Schematic illustration of the conformational change of cullin 3 by neddylation. Cu
regulated protein 8; Nrf2: nuclear factor erythroid 2 related factor 2; Keap1: BTB-Kelch
enzyme; Ub: ubiquitin.Cullin family proteins: cullin-based ubiquitin ligases
CRLs are multimeric complexes having a catalytic center in a
family member of proteins. Cullins are proteins that play a role in
post-translational modiﬁcation of proteins, including ubiquitina-
tion. The cullin family is highly conserved among species [15];
seven different cullins have been identiﬁed in mammals (Cul1, 2, 3,
4A, 4B, 5 and 7) [14,16].Structure of CRLs complexes
Each cullin forms a distinct class of CRL complex consisting of
different adapters and/or substrate recognition subunits [14,17].
Table 1 presents a list of the adapters associated with different
cullins.
The properties and the biological role of cullins are very different,
and while there are structural differences between these complexes,
collected evidence suggests that CRLs exert a key role in the regu-
lation and cell cycle control. In addition, these multimeric complexes
are involved in various cellular processes, including multiple aspects
of quality control of proteins, cell growth, signal transduction,
transcription and DNA replication, among others [14]. This diversity
of functions is given by each of the adapters present in the complex.
For example, the adapter S-phase kinase-associated protein 1 (Skp1)
mediates binding of F-box proteins to cullin 1 and cullin 7 [15],
and its molecular targets are p27, cyclin E and β-catenin, that are
involved in cell cycle regulation and signal transduction. In CRL4A,
the substrate recognition unit is composed of protein 1 damaged
DNA binding (DDB1), so its main function is to activate ribonucleo-
tide reductase (RNR). Cullins that require ElonginC or B protein as
the adapter are implicated in regulating the cell cycle by mediating
degradation of p53, a protein involved in the regulation of intracel-
lular oxygen concentration, and so, in the regulation of cell redox
homeostasis [18] (Table 1).Regulating the activity of CRLs
The activity of E3 ligases based on cullin is regulated through
the reversible conjugation of a small ubiquitin-type protein known
as Neural precursor cell expressed developmentally down-regu-
lated protein 8 (Nedd8). Covalent modiﬁcations of these cullins are
essential for its association with the E2 enzyme, so it can promote
ubiquitination of target proteins [19].
Nedd8 is a ubiquitin-like protein and is classiﬁed as type 1,
which means that it can combine with proteins to direct them to
secondary processes, such as ubiquitination. It is known that
Nedd8 is mainly bound to the family members of the cullins,l3: cullin 3 protein; Nedd8: Neural precursor cell expressed developmentally down-
-like ECH-associated protein 1; Rbx1: RING-box protein; E2: ubiquitin conjugating
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UPS [20]. The Nedd8 conjugation (neddylation process) to differ-
ent cullins is similar to ubiquitination, and is an ATP-dependent
process that is catalyzed by an E1 (Uba3/APP-BP1), where acti-
vated Nedd8 is transferred to an E2 (Ubc12), which in turn is
responsible for the polypeptide binding of cullin to Nedd8 [21,22].
Neddylation is given by the formation of an isopeptide bond,
linking the carboxyl-end of Nedd8 Gly-76 to the amino group of a
conserved cullin lysine residue, thereby increasing the conjugation
of ubiquitin ligase activity for promoting the recruitment of E2,
stimulating other conformational rearrangement in the B winged-
helix domain of the C-terminal subdomain, allowing RING cullin to
form a more “dynamic form”, and promoting the transfer of
ubiquitin to the substrate (Fig. 1) [20].CRL complex based on cullin 3 (CRL3)
Compared to other cullin-based complexes, the cullin complex
3 is quirky: it does not require different adapters in order to
recognize its target protein, but only requires a protein with a bric-
a-brac/tramtrack/broad-complex (BTB) domain to recognize it;
this property makes it even more interesting to study. Despite
the fact that BTB domains were originally found in transcription
factors of Drosophila melanogaster, it is now known that all
eukaryotic species express a variety of BTB domain proteins [23].
The establishment of structural homology between BTB proteins
with Skp1 or Elongin C (subunits of some CRLs) has served to
hypothesize that this type of BTB protein could also interact with
members of the cullin family, suggesting that various BTB proteins
interact with a member of this family, with cullin 3 (Cul3), but not
with other members [24,25]. This feature of BTB protein binding
allows Cul3 to participate in biological processes; however, in
recent years, the complex based on cullin 3 has been implicated
especially in processes such as the cell cycle regulation of redox
homeostasis, a process that must be of major interest since it is
related to chronic degenerative diseases where oxidative stress
plays a key role.The function of Cul3 in cell cycle regulation
Since the identiﬁcation of BTB domains initially found in Droso-
phila melanogaster, BTB domain proteins have also been found in
humans, where there are approximately 500 proteins identiﬁed; its
nomenclature is varied but the BTB protein family can be subdivided
into BTB-zinc ﬁnger (BTB-ZF), BTB-BACK-kelch (BBK), MATH-BTB,
BTB-NPH3, Kelch family (KLHL), and Kelch repeat and BTB domain-
containing proteins (KBTBD) subfamilies of proteins, among others
[23,26]. Many of these proteins have been speciﬁcally related with
Cul3 and its biological function is related with cell cycle regulation.
For example, one of the most studied proteins in this ﬁeld is theTable 2
Cul3-associated proteins and their function in different cellular processes.
Associated protein Function
KEL-8 Regulates off and on glutamate receptor at sy
Gigaxonin Promotes degradation MAP1B and cofactor M
NAC-1 Translocates UPS from the nucleus to the cyto
Keap1 Regulates proteasomal degradation of Nrf2.
Cyclin E Controls the S phase entry and maintains cell
MEL-26 Regulates the activity of MEI-1 in forming the
KLHL-7 A mutation in the KHLH-7 gene affects protei
MAP1B: Microtubule-associated protein 1B; MAP8B: Microtubule-associated protein 8;maternal lethal effect-26 protein (MEL26), which is a MATH-BTB
subfamily member (47 kDa) [27] that functions as a speciﬁc adapter
substrate for the E3 ligase. Cul3 draws the complex meiosis inhibitor
protein 1 (MEI-1) for degradation via interaction with its meprim and
TRAF homology domain (MATH). MEI-1 is a member of the AAA
ATPase family, and it is believed that short microtubules during the
mitosis/meiosis transition facilitate polar body extrusion. Thus,
MEL26 plays a dual role in early stages of development: it acts as
an adapter for Cul3 ubiquitin ligase to degrade MEI-1, while, on the
other hand, it functions as an activator of cytokinesis and is required
for efﬁcient actomyosin ring contraction, thereby controlling the
initiation and lasting of the cleavage furrow in Caenorhabditis elegans
[27,24]. The relevance of this process lies in the fact that the complex
based on Cul3 is required to degrade MEI-1 after meiosis, which is
essential for the assembly of a functional spindle [28]. It has been
observed that poor Cul3 ligase activity leads to an accumulation of
MEL26, and these elevated levels were correlated with MEL26
embryos containing short microtubules [27], so the Cul3-based E3
ligase functions as a regulator of MEL26 for cytokinesis, allowing the
accumulation only in the place and time. Hence, increasing the
activity of this protein could cause severe problems in the cytokinetic
process. Proper control of cell cycle progression is critical for the
maintenance of any cell; a special case are neurons because although
they are in G0, they have the ability to reactivate their cell cycle in
response to damage, despite this promoted re-entry of cell cycle of
postmitotic cells induces cell death instead of proliferation, which is a
common pathway shared in various neurodegenerative disorders
[29]. The mechanism by which the cell cycle is reactivated in such
cells is not well understood yet, but there is additional evidence about
the regulation of the Cul3/MEL-26 complex, pointing out the impor-
tance of the cullin in cellular regulation of this process; for example,
Moghe and colleagues [30] have shown that depletion of Cul3 or
KLHL18 proteins causes the cells to enter into mitosis. In addition,
Cul3 overexpression promotes the ubiquitination of Aurora-A both
in vivo and in vitro. Thus, Cul3 is able to regulate the entrance to
mitosis in an Aurora-A-dependent manner by interacting with
KLHL18 protein, hence mediating the activation of Aurora-A in
centrosome. This regulation is an important process because it has
been shown that there is deregulation in tumors of different kinases,
including Aurora-A, and pollo-like kinase 1 (PLK1) and the never in
mitosis gene a-related kinase 2 (Nek2) [30–33]. In turn, PLK1 is a
critical regulator of mitosis through its dynamic localization at
kinetochores, centrosomes and the middle zone; PLK1 has been
proven to be a target for protein E3 ubiquitin ligase complex based
on Cul3, and it is also recognized by a BTB protein called KLHL22. In
the absence of the adapter protein KLHL22, PLK1 is accumulated at
kinetochores, promoting the activation of the spindle assembly
checkpoint (SAC), which ensures that chromosome segregation takes
place correctly [34,35].
Another important molecule in regulating the cell cycle is
cyclin E. This is a highly conserved protein and is essential to
promote the transition from G1 to S phase in the cell cycle [36].Reference
napses. [40]
AP8B of tubulin. [41,42]
plasm in dendritic spines. [43]
[44,13]
s in a quiescent state. [36,37]
cytoskeleton in meiosis and mitosis. [45]
n binding to Cul3 and causes retinitis pigmentosa. [46]
NAC1: nucleus accumbens-1.
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of the cell cycle, because it is necessary for the G1/S. Cyclin E/Cdk2
complex phosphorylates p27, an inhibitor of cyclin D, inducing its
degradation, promoting the expression of cyclin A, and allowing
the entrance and progression of S phase after cyclin E is rapidly
degraded by the UPS system [37]. The overexpression of cyclin
E has often been seen in human diseases, particularly in breast
and ovarian cancer [38]. The regulating cyclin E degradation is
mediated by two cullin-dependent mechanisms, one based on
Cul1 and the other based on the complex Cul3. Evidence shows the
importance of Cul3 in cyclin E degradation, since the loss of Cul3 is
likely to contribute to tumor progression, a process attributed to
the deregulation of the cell cycle [39] (Table 2).Fig. 3. Schematic representation of the Keap1/Cul3/Nrf2 complex. Cul3: cullin
3 protein; Nedd8: Neural precursor cell expressed developmentally down-regu-
lated protein 8; Nrf2: nuclear factor erythroid 2 related factor 2; Keap1: BTB- Kelch-
like ECH-associated protein 1; Rbx: RING-box protein; E2: ubiquitin conjugating
enzyme; Ub: ubiquitin.Cullin 3 and its importance in the response to cellular stress
In recent years, it has been accepted that oxidative stress is
implicated in the development of various disorders, such as cancer
and neurodegenerative diseases. Therefore, the search for molecules
possessing cytoprotective properties against oxidative damage to
induce the expression of genes encoding enzymes of phase II by
the nuclear factor erythroid 2 related factor 2 (Nrf2)-mediated path-
way has proven to be a major research area (Fig. 2).
Nrf2 is constitutively expressed in most cells, so its activity
remains strictly regulated by the cell to maintain a particular
redox status, remaining in homeostasis. The most widely accepted
model that describes the regulation of Nrf2 function proposes that,
under homeostatic conditions, this factor is not free and active all
the time, but only when oxidative stress conditions are generated.
Also, this model suggests that Nrf2 is maintained primarily in
the cytoplasm, where it remains bound to the BTB-Kelch-like
ECH-associated protein 1 (Keap1 or KLHL19); therefore, low levels
remain in the rest of the cell [47–50] (Fig. 2). Its localization in the
cytoplasm is mainly due to an interaction between Neh2 domain
of Nrf2 with a domain of Keap1 referred to as DGR domain, which
is comprised of six repeats of double glycine [44,51].
Keap1 is a Kelch-like protein with the BTB domain, which is
bound to Cul3 [52,53]. Numerous studies refer to the importance of
Cul3 in the regulation of Nrf2 activity, since it has been found that. 2. Mechanism of Nrf2 regulation. Cul3: cullin 3 protein; Nedd8: Neural precursor c
throid 2 related factor 2; Keap1: BTB-Kelch-like ECH-associated protein 1; Rbx1: RING-bo
PI3K: phosphoinositol 3-kinase; PERK: protein kinase RNA-like endoplasmic reticulum
cogen synthase kinase 3; FYN: non-receptor tyrosine kinase; ARE: antioxidant responsethis transcription factor is present in Cul3 complexes in vivo,
constitutively leading to Nrf2 degradation via UPS [51,54] (Fig. 3).
Also, it has been found that alterations in both Keap1 BTB domain
and modiﬁed Cys151 of Keap1 Cul3 affect the binding of the latter,
thereby decreasing the ubiquitination of Nrf2 [54,55]. In addition,
it has been shown that Cul3 overexpression is associated with
increased susceptibility to carcinogenes and oxidative stress in
breast cancer because this overexpression contributes to the deple-
tion of Nrf2 levels [56]. Altogether, this evidence has served to
suggest that, far from being just a protein involved in a complex
that directs the degradation of Nrf2 via UPS, Cul3 could be a
determining factor in the regulation of the activity of Nrf2 during
stress responses. Evidence also suggests that deregulation of Keap1
activity is strongly implicated in the development of resistance to
chemotherapeutic drugs [57,29], or in the development of some
cancers [58,59] through Nrf2 activation, thus allowing the expres-
sion of regulatory molecules with high capacity, including Cul3,
since this is intimately related to the ability to regulate the levels of
Keap1 and Nrf2 [60].
Recently, it was found that nucleus accumbens-1 (NAC1), a
transcription factor that belongs to the bric-a-brac, tramtrack,
broad complex/Pox virus and zinc ﬁnger family (BTB/POZ),
responds to cellular stress and modulates the process of auto-
phagy. NAC1 inactivates autophagy and suppresses apoptosis inell expressed developmentally down-regulated protein 8; Nrf2: nuclear factor
x protein; E2: ubiquitin conjugating enzyme; Ub: ubiquitin; PKC: protein kinase
kinase; MAPK: mitogen-activated protein kinase; CK2: Casein kinase 2; GSK3b:
element.
Table 3
Cul3-associated proteins and their relevance to the renal system.
Associated protein Function Reference
KLHL3/WNK4 Loss in the ability of the complex to ubiquitinate WNK4 KLHL3/Cul3 and therefore, to regulate the levels of ROMK carried PHAII.
WNK4 regulates the activity of the Na+/Cl- co-transporter (NCC), the epithelial Na+ channel (ENaC), the K+ channel (ROMK) and the
Cl-/HCO3- exchanger. ROMK / H+ ATPase are required for secretion of renal K+ and H+. Patients with Cul3 mutations have severe
hyperkalemia metabolic acidosis.
[73,68]
KLHL3/WNK1 WNK1 exerts its effect on blood pressure through its ability to phosphorylate and activate kinases like SPAK/STK39 and OSR1.
Increased expression of WNK4 stimulates an abnormal retention of salt in the kidney by the activation of NCC and NKCC2 (Na–K–Cl)
co-transporters.
[70]
KLHL3/WNK4/OSR1 Activation of NKCC1 co-transporters, and NCC/NKCC2 by OSR1, plays a critical role in the
regulation of blood pressure and renal resorption of NaCl.
[74]
WNK4: With-no-lysine (K) kinase-4; WNK1: With-no-lysine (K) kinase-1; OSR1: oxidative stress-responsive 1 protein; ROMK: renal outer medullary potassium channel;
PHAII: pseudohypoaldosteronism type II; SPAK: STE20/SPS1-related, proline alanine-rich kinase; STK39: serine threonine kinase 39.
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important regulator of these cellular processes [61]. It has been
observed that NAC1 is highly regulated in several tumor types,
such as breast cancer, renal cell carcinoma and hepatocellular
carcinoma, and it has been identiﬁed as a chemo-resistance gene
[62,63]. Besides this, NAC1 is relevant because it regulates the UPS
translocation from the nucleus to the cytoplasm in dendritic
spines, a process mediated by Cul3 binding [43]. This evidence
shows that Cul3 is a protein involved in diverse cellular processes,
including the consolidation of the UPS functions.
Another protein that can be indirectly regulated by Cul3
through the action of Nrf2 is the multidrug resistance-associated
protein-1 (MRP1), which has emerged as an important contributor
to chemoresistance. MRP1 is induced by oxidative stress [64,65];
the molecular mechanism for the induction of this protein has not
been clariﬁed yet, but evidence indicates that the induction of
phase II enzymes and the multidrug resistance proteins (MRPs) is
similar, conﬁrming that Nrf2 is required for the constitutive and
inducible expression of MRP1; however, how Nrf2 mediates the
transcriptional activation of MRP1 remains unclear [64,66].
Moreover, in Arabidopsis, the reduction of Cul3 function leads
to increased protein ATHB6 (a HD-ZIP type transcription factor)
accumulation, reducing plant growth and fertility, and affecting
the stomatal behavior and responses to abscisic acid (ABA), a plant
hormone which response is crucial for biotic and abiotic stress. This
clearly shows that Cul3 is important in signaling pathways for rapid
adaptation that allows growth and cell survival [67].
Currently, the study of the involvement of Cul3 in disease
development is booming. Including the latest research, Cul3 has
been linked to the development of pseudohypoaldosteronism type
II (Gordon's hypertension syndrome/PHAII); in this disease, muta-
tions have been identiﬁed in KLHL3 [68], which is a protein family
BTB-BACK-Kelch, which serves as a substrate for Cul3 adapter
KLHL3 and is highly expressed in the distal tubules of the nephron,
where it is involved in the regulation of the electrolyte home-
ostasis and blood pressure [69]. Cul3 could be a new candidate
protein presenting development-related PHAII type mutations.
The existence of these mutations was conﬁrmed and coupled
with Cul3 ubiquitous expression in all segments of the nephron,
suggesting that CRL E3 is critical in regulating hypertension
[70,68]. Chronic kidney disease has been associated with hyper-
tension, mitochondrial dysfunction and oxidative stress [71], so
the study of the function of Cul3 in these conditions is critical.
Distal myopathy is another example where Cul3 activity has been
linked to the development of pathologies. In this case, a mutation
has been identiﬁed in the gene coding for the BTB Kelch-like
protein 9 (KLHL9), which is capable of interfering with the
interaction with Cul3 [69,72], thereby affecting the ubiquitination
of their substrates [73] (Table 3).Cullin 3 as a therapeutic target
Through selective degradation of these substrates, E3 ligases
regulate many biological processes and are considered as mole-
cules with a high therapeutic potential for regulation of events
that are mainly related to the development of cancer and chronic
degenerative diseases.
In recent years, several groups have investigated the ability of
modulating the neddylation pathway of CRLs, in order to reduce
the toxicity caused by drugs that inhibit proteasome activity as a
therapeutic strategy. This strategy has been used to treat a variety of
different diseases related to the alteration in the UPS activity, such as
the initiation or progression of tumors (astrocytomas, hemangio-
blastomas and medulloblastomas), as well as some neurodegenera-
tive diseases [8,75]. Because of the emergence of resistance to
proteasome inhibitors, selective novel inhibitors are being developed
[75,76]. This is the case for new inhibitors directed against speciﬁc
components of the UPS, like the Nedd8-activating enzyme, which is a
protein required for the neddylation process, thus promoting the
activity of CRLs [20,77], a strategy currently implemented for the
treatment of several types of cancer [78–81].
Therefore, studying the Cul3 protein complexes is relevant to
direct therapeutic strategies not only against cancer, but also
against disorders that have been largely related with oxidative
stress by regulating the Nrf2 pathway. Also, it is relevant in the
treatment of neurodegenerative diseases by regulating the cell
cycle progression, and in renal pathologies by regulating kinases
activity involved in the normal renal system function, two areas
that have not yet been widely explored.
It is noteworthy that one of the advantages for Cul3 targeted
therapy is that it would be more speciﬁc for the regulation of
certain substrates, as well as the reduction of toxicity because it
does not inhibit bulk proteasomal degradation. However, the
activity of Cul3 must be carefully analyzed to understand the
mechanisms by which it regulates some cellular processes above-
mentioned. Of note is that a bad therapeutic manipulation of this
target could trigger cell abnormalities that could lead to cell death.Conclusion
The importance to highlight the evidence aforementioned is
because it allows conducting research to identify other BTB-proteins
involved in diseases, thereby suggesting a shared participation of Cul3
in the development of pathologic conditions. The deregulation of Cul3
activity could be a mechanism involved in pathologies mainly asso-
ciated with oxidative stress and cell cycle deregulation. Therefore,
strategies oriented against Cul3 activity comprise a high therapeutic
A.C. Andérica-Romero et al. / Redox Biology 1 (2013) 366–372 371potential for regulation of cellular processes related to the develop-
ment of several pathologies.
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